Amedisys Announces New $70 Million Second Lien Credit Facility and Amendment
to Senior Secured Credit Facility
BATON ROUGE, La., July 29, 2014 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ
"AMED" and the "Company"), one of America's leading home health and hospice
care companies, today announced that it entered into a new $70 million
six-year second lien term loan facility. In connection with the new second
lien facility, the Company's existing senior secured credit facility was
amended and downsized to $159 million, consisting of an existing term loan
with a balance of $39 million and a $120 million revolving credit facility.
The maturity of the senior secured facility will remain unchanged.
Proceeds from the new term loan were used to pay down outstanding revolver
balances. The interest rate of the second lien term loan is priced at LIBOR
plus 7.5% with a 1.0% LIBOR floor. More details on the facility will be
provided in the company's SEC filing 10-Q on July 30, 2014.
Ronald A. LaBorde, president and interim chief executive officer of Amedisys,
Inc. stated, "This new six-year facility, in combination with our amended
senior facility, will support our capital needs as Amedisys continues to
implement both short-term and long-term performance improvement initiatives."
Amedisys, Inc. is headquartered in Baton Rouge, La. and our common stock
trades on the NASDAQ Global Select Market under the symbol AMED.
Amedisys, Inc. (Nasdaq:AMED) is a "health care at home" company delivering
personalized home health and hospice care to more than 360,000 patients each
year. Amedisys is focused on delivering the care that is best for our
patients, whether that is home-based recovery and rehabilitation after an
operation or injury, care focused on empowering them to manage a chronic
disease, palliative care for those with a terminal illness, or hospice care at
the end of life. For more information about Amedisys, please visit:
We use our company website as a channel of distribution for important company
information. Important information, including press releases, analyst
presentations and financial information regarding the Company is routinely
posted on and accessible on the "Investor Relations" subpage of our website,
which is accessible by clicking on the tab labeled "Investors" on our website
home page. We will also use our website to expedite public access to
time-critical information regarding the Company in advance of or in lieu of
distributing a press release or a filing with the Securities and Exchange
Commission ("SEC") disclosing the same information. In addition, we make
available on the Investor Relations subpage of our website (under the link
"SEC filings") free of charge our annual reports on Form 10-K, quarterly
reports on Form 10-Q, current reports on Form 8-K, ownership reports on Forms
3, 4 and 5 and any amendments to those reports as soon as practicable after we
electronically file such reports with the SEC. Further, copies of our
Certificate of Incorporation and Bylaws, our Code of Ethical Business Conduct
and the charters for the Audit, Compensation, Nominating and Corporate
Governance, Quality of Care and Compliance and Ethics Committees of our Board
are also available on the Investor Relations subpage of our website (under the
link "Corporate Governance").
CONTACT: Amedisys, Inc.
Amedisys, Inc. logo
Press spacebar to pause and continue. Press esc to stop.